ADXN

Addex Therapeutics Ltd operates as a clinical-stage biopharmaceutical company focused on developing allosteric modulator drug candidates for neurological disorders. Headquartered in Geneva, Switzerland, the company specializes in targeting G protein-coupled receptors (GPCRs) using its proprietary allosteric modulator platform technology. Addex's pipeline includes ADX71149, a mGlu2 positive allosteric modulator in development for epilepsy and other neurological conditions, and ADX71441, a mGlu7 negative allosteric modulator being evaluated for post-traumatic stress disorder. The company also develops dipraglurant, an mGlu5 negative allosteric modulator licensed to Indivior for substance use disorders, from which Addex receives milestone payments and royalties. Addex trades on the SIX Swiss Exchange under the ticker symbol ADXN and maintains strategic partnerships with pharmaceutical companies to advance its clinical programs. The company's business model centers on discovering and developing novel allosteric modulators through early-stage clinical development, then partnering with larger pharmaceutical firms for late-stage trials and commercialization. In recent developments, Addex continues to advance its clinical pipeline with ADX71149 showing potential in treatment-resistant focal epilepsy studies. The company employs approximately 20 people and operates research facilities in Switzerland, focusing its resources on GPCR drug discovery and clinical development activities.